Clinical Trial Update: Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating SEP-363856 in male and female volunteers with varying schizotypy characteristics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED